

Welchol® (colesevelam) – New formulation approval

- On April 3, 2019, the <u>FDA approved</u> Daiichi Sankyo's <u>Welchol (colesevelam)</u> chewable bars, as an
 adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults
 with primary hyperlipidemia and as an adjunct to diet and exercise to improve glycemic control in
 adults with type 2 diabetes mellitus.
 - Welchol is indicated to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years
 of age, with heterozygous familial hypercholesterolemia who are unable to reach LDL-C
 target levels despite an adequate trial of dietary therapy and lifestyle modification.
 - Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.
 - The effect of Welchol on cardiovascular morbidity and mortality has not been determined.
 - Welchol has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase 4 inhibitor.
 - Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.
 - Welchol has not been studied in children younger than 10 years of age or in premenarchal girls.
- The approval of Welchol chewable bars was based on studies conducted with Welchol tablets.
- Welchol is contraindicated in patients with:
 - Serum TG concentrations > 500 mg/dL
 - History of hypertriglyceridemia-induced pancreatitis
 - A history of bowel obstruction
- Warnings and precautions of Welchol include hypertriglyceridemia and pancreatitis, gastrointestinal obstruction, vitamin K or fat-soluble vitamin deficiencies, drug interactions, risks in patients with phenylketonuria, and macrovascular outcomes.
- The most common adverse reactions (≥ 2% and greater than placebo) with Welchol use were constipation, dyspepsia, and nausea.
- The recommended dosage of Welchol is 3.75 grams (one chewable bar) daily, with a meal. Welchol
 chewable bars contain approximately 80 calories per bar.
- Daiichi Sankyo's launch plans for Welchol chewable bars are pending. Welchol chewable bars will be available in a 3.75 gram strength (chocolate, strawberry, and caramel flavors).



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.